TLPH Talphera, Inc.
USHealthcareAs of 2026-08-17
Why TLPH matters now
Talphera, Inc. (TLPH) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.20 with -2.44% on the session and $62.3M in market capitalization; recent performance reads 1-month +31.04% and YTD -4.39%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.6M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -50.5%.
The latest indexable market news headline is "Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Aslam Shakil filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.50
P/S
22363.11
EV/EBITDA
-1.30
DCF Value
$-0.03
FCF Yield
-50.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-1451600.0%
Net Margin
-1425300.0%
ROE
-93.0%
ROA
-47.3%
ROIC
-55.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.6M | $-0.06 |
| Q4 2025 | $0.00 | $-3.8M | $-0.09 |
| FY 2025 | $28.0K | $-14.3M | $-0.34 |
| Q3 2025 | $1.0K | $-4.4M | $-0.11 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.76
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.